15 May 2019
Scintomics and 1717 Life Science Ventures Team up
Scintomics and 1717 LSV to collaborate in the development of novel cancer diagnostics and treatment.
Read more
2 May 2018
Blue Earth Diagnostics Expands Oncology Portfolio with Exclusive, Worldwide Licensing of Investigational Radiohybrid PSMA-targeted Agents for Prostate Cancer from Scintomics
Blue Earth Diagnostics has acquired the exclusive worldwide rights to a broad family of Prostate Specific Membrane Antigen (PSMA)-targeted radiohybrid (“rh”) agents for cancer imaging, together with an exclusive option to explore therapeutic applications.
Read more- 1
- 2